Overview
Nawaloka Hospitals provides private inpatient, outpatient, diagnostic and specialist clinical services, alongside digital-health and international-patient offerings. The latest quarter shows a split picture: hospital operations expanded and gross profitability improved, but more of operating profit was absorbed by finance costs, tax and other below-operating items, leaving less profit for ordinary shareholders.
Price performance
NHL closed at LKR 10.50 on 29 October 2026. It fell 20.4% over three months against a 4.2% decline in the ASPI, so its retreat was materially steeper than the broad market's over the same period. The share stood 13.5% of the way up its 52-week range, close to its annual low rather than its high.
Sixty-day volatility was 40.4% below its own one-year level, while 20-day volume was 28.8% above its 60-day norm, indicating quieter price swings alongside somewhat higher recent trading activity. The record is five falls of 15% or more in three years, the deepest 44%, which has not yet recovered. Median daily turnover was LKR 647,002, and a LKR 1 million order is more than everything that trades on a typical day (155% of it), making that order a large part of a normal session.
Valuation
At 14.0 times earnings, a buyer pays LKR 14 for every LKR 1 of trailing profit, versus the healthcare median of 9.83 times. The P/B of 2.17 means paying LKR 2.17 for each LKR 1 of net assets and sits above the sector median, while the audited return on equity was 16.3% for the year ended March 2026, which partly supports a premium to book value.
The shares carry a 0% dividend yield and no dividend is on record in the last two years. On NHL's own record, the P/B was more expensive than at 10 of 11 recorded year-ends. The current price also relies materially on the latest quarter, which supplied 42.8% of trailing EPS; that concentration makes the trailing multiple depend heavily on one quarter's earnings.
News and sentiment
Direct coverage is thin: two material articles in the past 90 days were positive, both reporting on 19 October 2026 that NHL increased its Digital Health, the Doc990 operator, stake to 12.12%. NHL's reported LKR 62.72 million purchase increases its exposure to the associate, but the articles do not disclose the earnings contribution, so its effect on group profit cannot be sized.
Financials
September-quarter revenue rose 8.9% year-on-year to LKR 3.9 billion and operating profit rose 6.8% to LKR 652 million, but net profit fell 8.2% to LKR 270 million. The LKR 382 million gap between operating and net profit was larger than a year earlier, so growth in clinical operations did not fully reach the earnings represented by each share.
Gross margin improved from 56.0% to 57.5%, operating margin eased from 17.3% to 16.9%, and net margin fell from 8.3% to 7.0%. The gross margin was the best September-quarter result in seven comparable filings, but operating and net margins were middling against prior September quarters. That distinction matters: the core service margin improved, while expenses below operating profit reduced the final return.
The latest figures end at 30 September 2026. The ordinary share count was unchanged at 1.4 billion, so the lower quarterly profit is not a mechanical per-share effect from a corporate action.
Risks
The principal risk is funding pressure. At the March 2026 year-end, debt equalled 111.8% of owners' equity, meaning borrowings exceeded the equity attributable to ordinary shareholders. Interest cover was 1.73 times, meaning operating profit covered the interest bill fewer than twice, leaving limited room if operating earnings weaken or finance costs rise.
The current ratio was 0.62 times: NHL had 62 cents of short-term assets, including receivables and inventories, for every LKR 1 of bills due within a year. Cash conversion was 0.44 times, so only 44 cents of each LKR 1 of operating profit arrived as operating cash during the year, an important check on reported earnings when debt remains high.
Government bond yields rose and the rupee weakened in the market backdrop through 29 October 2026. The data does not quantify NHL's exposure, but these conditions are relevant to the cost of funding and imported medical inputs.
Outlook
As at 29 October 2026, the next scheduled evidence is the December 2026 interim quarter, expected between 4 and 14 February 2027. It will show whether the stronger gross margin is translating into net profit after finance costs and other below-operating charges.
The Digital Health associate investment is a separate item to monitor, but the available reporting gives no earnings terms or contribution estimate. This data therefore cannot establish whether the increased stake will be meaningful to NHL's profit.